In this systematic review and meta-analysis involving 3 RCTs and 1,431 patients, we compared carboplatin and paclitaxel plus PD-1/PD-L1 inhibitors against carboplatin and paclitaxel olone for patients with primary advanced or recurrent endometrial cancer. This evidence concerns the gene PDCD1 and endometrial cancer.